x
Filter:
Filters applied
- Coronavirus (COVID-19) Collection
- EditorialRemove Editorial filter
- 2020 - 2022Remove 2020 - 2022 filter
Author
- Abubakar, Aisha1
- Aklillu, Eleni1
- Al-Abri, Seif1
- Ansumana, Rashid1
- Asogun, Danny1
- Azhar, Esam I1
- Bates, Matthew1
- Blumberg, Lucille1
- Bockarie, Moses1
- Chakaya, Jeremiah1
- Cruz, Cintia1
- Dotan, Arad1
- Edwards, Sarah1
- Haider, Najmul1
- Hamid, Muzamil Mahdi Abdel1
- Himwaze, Cordelia M1
- Hui, David S1
- Ippolito, Giuseppe1
- Kaleebu, Pontiano1
- Kapata, Nathan1
- Kock, Richard1
- Kramer, Laura D1
- Maeurer, Markus1
- Mboera, Leonard1
- McHugh, Timothy D1
Coronavirus (COVID-19) Collection
4 Results
- EditorialOpen Access
Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) - highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts
International Journal of Infectious DiseasesVol. 114p268–272Published online: December 1, 2021- Eskild Petersen
- Francine Ntoumi
- David S Hui
- Aisha Abubakar
- Laura D. Kramer
- Christina Obiero
- and others
Cited in Scopus: 87Nearly two years since the start of the SARS-CoV-2 pandemic, which has caused over 5 million deaths, the world continues to be on high COVID-19 alert. The World Health Organization (WHO), in collaboration with national authorities, public health institutions and scientists have been closely monitoring and assessing the evolution of SARS-CoV-2 since January 2020 (WHO 2021a; WHO 2021b). The emergence of specific SARS-CoV-2 variants were characterised as Variant of Interest (VOI) and Variant of Concern (VOC), to prioritise global monitoring and research, and to inform the ongoing global response to the COVID-19 pandemic. The WHO and its international sequencing networks continuously monitor SARS-CoV-2 mutations and inform countries about any changes that may be needed to respond to the variant, and prevent its spread where feasible. - EditorialOpen Access
Post-COVID syndrome: the aftershock of SARS-CoV-2
International Journal of Infectious DiseasesVol. 114p233–235Published online: November 13, 2021- Arad Dotan
- Yehuda Shoenfeld
Cited in Scopus: 9Significant time has passed since the coronavirus disease of 2019 (COVID-19) pandemic outbreak, which led to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection in hundreds of millions of individuals all around the globe. An accumulation of evidence during the pandemic raised awareness of an association between the SARS-CoV-2 and autoimmunity (Dotan et al., 2021 Apr). SARS-CoV-2 infected patients have a high presence of various autoantibodies (Dotan et al., 2021 Apr). Moreover, numerous cases of new-onset of autoimmune-related disorders have been documented following infection, including both organ-specific and systemic autoimmune diseases (Dotan et al., 2021 Apr). - EditorialOpen Access
COVID-19 chemoprevention
International Journal of Infectious DiseasesVol. 107p31–33Published online: April 23, 2021- Cintia Cruz
- Nicholas J. White
Cited in Scopus: 0Despite the enormity of COVID-19 pandemic and the many hundreds of clinical trials evaluating putative therapeutics, there have been very few randomised controlled trials (RCTs) of COVID-19 pre-exposure prophylaxis. RCTs provide the strongest evidence in this setting (Collins et al., 2020). This is particularly important in the politicised and febrile arena of COVID-19 medicines where claims and counter claims abound, and good clinical science has suffered. In this edition of IJID Seet et al. report a detailed and well conducted open cluster randomised trial of five different pre-exposure interventions in male migrant workers quarantined in isolated dormitories in Singapore (Seet et al., 2021). - EditorialOpen Access
COVID-19: A PCR-defined pandemic
International Journal of Infectious DiseasesVol. 103p278–279Published online: November 30, 2020- Thirumalaisamy P. Velavan
- Christian G. Meyer
Cited in Scopus: 10The numbers of coronavirus disease 2019 (COVID-19) cases are increasing steadily in many parts of the world, and the global and devastating impact of the current pandemic on all aspects of our life is evident. The number of positive molecular diagnostic tests, which are largely based on real-time (RT) PCR assays that detect genetic material of the causative agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), still forms the basis for reporting both symptomatic and asymptomatic cases worldwide.
